Similar articles

• Autolymphocyte therapy. III. Effective adjuvant adoptive cellular therapy with in vivo anti-tumor specificity against murine melanoma and carcinoma using ex-vivo-activated memory T-lymphocytes.

  Gold JE, Masters TR, Osband ME. Gold JE, et al. J Surg Res. 1995 Aug;59(2):279-86. doi: 10.1006/jsre.1995.1165. J Surg Res. 1995. Retraction in: J Surg Res. 1998 Feb 1;74(2):196. PMID: 7543632 Retracted.
• Autolymphocyte therapy-1. In vivo tumor-specific adoptive cellular therapy of murine melanoma and carcinoma using ex vivo activated memory T-lymphocytes.

  [No authors listed] [No authors listed] Eur J Cancer. 1998 May;34(6):946. Eur J Cancer. 1998. PMID: 9840962 No abstract available.
• Autolymphocyte therapy in the treatment of metastatic renal cell carcinoma.

  Sawczuk IS. Sawczuk IS. Urol Clin North Am. 1993 May;20(2):297-301. Urol Clin North Am. 1993. PMID: 8493751 Review.
• Adoptive immunotherapy of hormone-refractory, stage D2 prostate cancer using ex vivo activated autologous T cells (autolymphocyte therapy): results from a pilot study.

  Ross S, Liu V, Abulafia R, Hogan C, Osband M. Ross S, et al. Biotechnol Ther. 1993;4(3-4):197-211. Biotechnol Ther. 1993. PMID: 7507387 Clinical Trial.
• Is antigen specificity the key to efficient adoptive T-cell therapy?

  Labarriere N, Khammari A, Lang F, Dreno B. Labarriere N, et al. Immunotherapy. 2011 Apr;3(4):495-505. doi: 10.2217/imt.11.16. Immunotherapy. 2011. PMID: 21463191 Review.